

# PCT

## INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

27 JAN 2005

Applicant's or agent's file reference <b>37629-0064</b>	<b>FOR FURTHER ACTION</b>	see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below:
International application No. <b>PCT/IB 03/03681</b>	International filing date (day/month/year) <b>30/07/2003</b>	(Earliest) Priority Date (day/month/year) <b>30/07/2002</b>

Applicant

**MORPHOSYS IP GMBH**

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of **04** sheets.

It is also accompanied by a copy of each prior art document cited in this report.

**1. Basis of the report**

- a. With regard to the language, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

- b. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of the sequence listing :

contained in the international application in written form.

filed together with the international application in computer readable form.

furnished subsequently to this Authority in written form.

furnished subsequently to this Authority in computer readable form.

the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2.  Certain claims were found unsearchable (See Box I).

3.  Unity of invention is lacking (see Box II).

4. With regard to the title,

the text is approved as submitted by the applicant.

the text has been established by this Authority to read as follows:

5. With regard to the abstract,

the text is approved as submitted by the applicant.

the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the drawings to be published with the abstract is Figure No.

as suggested by the applicant.

because the applicant failed to suggest a figure.

because this figure better characterizes the invention.

**01**

None of the figures.

**A. CLASSIFICATION OF SUBJECT MATTER**  
**IPC 7 C12N15/10**

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

**IPC 7 C12N**

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**EPO-Internal, BIOSIS, EMBASE, MEDLINE, WPI Data, PAJ**

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2002/034733 A1 (LOHNING CORINNA) 21 March 2002 (2002-03-21) paragraphs '0007!, '0015!, '0118!, '0130!, '0132!, '0134! - '0136!, '0138!, '0153! - '0156!; claims 1,11,12,15,16	1-19
Y	BRINKMANN U ET AL: "Phage display of disulfide-stabilized Fv fragments" JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V., AMSTERDAM, NL, vol. 182, no. 1, 11 May 1995 (1995-05-11), pages 41-50, XP004021178 ISSN: 0022-1759 abstract figure 1	1-19

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

\* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*&\* document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

12 October 2004

02/11/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5618 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.  
Fax (+31-70) 340-3016

Authorized officer

Surdej, P

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>BURGER C ET AL: "An integrated strategy for the process development of a recombinant antibody-cytokine fusion protein expressed in BHK cells"  <i>APPLIED MICROBIOLOGY AND BIOTECHNOLOGY</i>, vol. 52, no. 3, September 1999 (1999-09), pages 345-353, XP002299887  ISSN: 0175-7598  abstract  figure 1</p> <p>-----</p>	1-39
Y	<p>HANNIG H ET AL: "Tricistronic recombinant adenovirus expressing clone specific immunoglobulin and enhanced green fluorescent protein (eGFP) as genetransfer vector for immunotherapy in non-Hodgkin Lymphoma"  <i>BLOOD</i>, vol. 96, no. 11 Part 2, 16 November 2000 (2000-11-16), page 379b, XP009037810  &amp; 42ND ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY; SAN FRANCISCO, CALIFORNIA, USA; DECEMBER 01-05, 2000  ISSN: 0006-4971  abstract</p> <p>-----</p>	1-39

Patent document cited in search report	Publication date		Patent family member(s)	Publication date
US 2002034733 A1	21-03-2002	AU	5986400 A	05-02-2001
		CA	2347973 A1	25-01-2001
		WO	0105950 A2	25-01-2001
		EP	1144607 A2	17-10-2001
		JP	2003505025 T	12-02-2003
		NO	20011386 A	18-05-2001